Theravance Biopharma Inc expected to post a loss of 11  cents a share - Earnings Preview

Theravance Biopharma

30/04/2022 03:05

* Theravance Biopharma Inc  TBPH.OQ   TBPH.O  is expected
to show
a rise in quarterly revenue when it reports  results on May 2
(estimated). 
    * The George Town Grand Cayman-based  company is expected to
report  a 1.6% increase in revenue to $14.484 million from
$14.26 million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Theravance
Biopharma Inc
is for a loss of 11 cents per share. For the same quarter last
year, the company reported a loss of $1.24 per share.
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts had risen by
about 7.7%
in the last three months. ​
    * Wall Street's median 12-month price target for Theravance
Biopharma Inc is $10​, above​ its last closing price of $9.65.
​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.32       -0.33      -0.43     Missed  -29.7
 Sep. 30 2021  -0.56       -0.56      -0.48     Beat    14.1
 Jun. 30 2021  -1.02       -1.00      -0.80     Beat    19.9​
 Mar. 31 2021  -1.05       -1.05      -1.24     Missed  -18.3
 ​​Dec.        -1.02       -1.02      -0.92     Beat    9.4
 31 2020                                                
 Sep. 30 2020  -0.99       -1.01      -1.16     Missed  -14.5​
 Jun. 30 2020  -0.98       -0.98      -1.00     Missed  -2.4
 Mar. 31 2020  -1.09       -1.07      -1.40     Missed  -30.2
 This summary was machine generated April 30 at 02:04 GMT.  All
figures in US dollars  unless otherwise stated